Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab - Results of the Diabetes Abciximab SteNT Evaluation (DANTE) randomized trial | |
Article | |
关键词: PERCUTANEOUS CORONARY INTERVENTION; NEOINTIMAL TISSUE PROLIFERATION; PLATELET IIB/IIIA INHIBITOR; LEUKOCYTE INTEGRIN MAC-1; GLYCOPROTEIN IIB/IIIA; RESTENOSIS; MELLITUS; BLOCKADE; OUTCOMES; IMPLANTATION; | |
DOI : 10.1161/01.CIR.0000116752.12261.D4 | |
来源: SCIE |
【 摘 要 】
Background - In diabetic patients in the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial, abciximab reduced target vessel revascularization by approximate to 50% compared with placebo. Whether this is a result of a lower restenosis rate caused by inhibition of intimal hyperplasia remains to be defined. Methods and Results - The purpose of this study was to determine whether abciximab at the time of stent implantation would reduce in-stent intimal hyperplasia measured by intravascular ultrasound at 6-month follow-up in type 2 diabetics. Ninety-six diabetic patients ( 96 lesions) who underwent elective stent implantation for a de novo lesion in a native coronary artery were randomly assigned to receive abciximab or no abciximab. In-stent intimal hyperplasia volume, expressed as percentage of stent volume, did not differ between groups: 41.3 +/- 21.0% for those treated with abciximab versus 40.5 +/- 18.3% for those treated without abciximab ( P = 0.9). There were also no significant differences in angiographic minimal luminal diameter at follow-up ( 1.74 +/- 0.69 versus 1.66 +/- 0.63 mm; P = 0.5), late loss ( 1.03 +/- 0.63 versus 1.07 +/- 0.58 mm; P = 0.7), restenosis rate (17.8% versus 22.9%; P = 0.5), or cumulative incidence of major adverse cardiac events at 12 months ( 19.1% versus 20.4%; P = 0.9). Conclusions - Six-month intravascular ultrasound volumetric analysis showed that abciximab, at the time of coronary stent implantation, was not associated with a reduction of in-stent intimal hyperplasia in diabetic patients.
【 授权许可】
Free